Multiple Dose IP Vancomycin Kinetics during CAPD

  • M. C. Rogge
  • P. G. Welling
  • C. A. Johnson
  • S. W. Zimmerman


Kinetics of vancomycin were studied in five noninfected CAPD patients given repeated IP doses. More than 60% of the first dose was absorbed and absorption from later exchanges was slightly lower. The volume of distribution increased for 18 h but plasma concentrations were maintained by repeated dosing.


Peritoneal Dialysis Vancomycin Concentration Dwell Period Intermittent Peritoneal Dialysis Noninfected Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vas S, and Low D: Peritonitis. In Nolph KD (Ed), Peritoneal dialysis. The Hague: Martinus Nijhoff, 1981, p 344CrossRefGoogle Scholar
  2. 2.
    Krothapalli RK, Senekjian HO, and Ayus JC: Efficacy of intravenous vancomycin in the treatment of gram-positive peritonitis in long-term peritoneal dialysis. Am J Med 75: 345, 1983PubMedCrossRefGoogle Scholar
  3. 3.
    Nielsen HE, Sorensen I, and Hansen HE: Peritoneal transport of vancomycin during peritoneal dialysis. Nephron 24: 274, 1979PubMedCrossRefGoogle Scholar
  4. 4.
    Rubin J, Ray R, Barnes T, and Bower J: Peritoneal abnormalities during infectious episodes of continuous ambulatory peritoneal dialysis. Nephron 29: 124, 1981PubMedCrossRefGoogle Scholar
  5. 5.
    Ayus JC, Eneas JF, Tong TG, Benowitz NL, Schoenfeld PY, Hadley KL, Becker CE, and Humphreys MH: Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis. Clin Nephrol 11: 129, 1979PubMedGoogle Scholar
  6. 6.
    Magera BE, Arroyo JC, Rosansky SJ, and Postic B: Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis. Antimicrob Agents Chemother 23: 710, 1983PubMedCrossRefGoogle Scholar
  7. 7.
    Pancorbo S, and Comty C. Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis. Nephron 31: 37, 1982PubMedCrossRefGoogle Scholar
  8. 8.
    Bunke CM, Aronoff GR, Brier ME, Sloan RS, and Luft FC. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 34: 631, 1983PubMedCrossRefGoogle Scholar
  9. 9.
    Cunha BA, and Ristuccia AM: Clinical usefulness of vancomycin. Clin Pharm 2: 417, 1983PubMedGoogle Scholar
  10. 10.
    Matzke GR, McGory RW, Halstenson CE, and Keane WF: Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25: 433, 1984PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • M. C. Rogge
    • 1
  • P. G. Welling
    • 1
  • C. A. Johnson
    • 1
  • S. W. Zimmerman
    • 1
  1. 1.Schools of Pharmacy and MedicineUniversity of WisconsinMadisonUSA

Personalised recommendations